The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company's current earnings (TTM) are $6.25 B. In 2022 the company made an earning of $13.47 B an increase over its 2021 earnings that were of $12.98 B.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | $6.25 B | -53.62% |
2022 | $13.47 B | 3.76% |
2021 | $12.98 B | 282.25% |
2020 | $3.39 B | -59.67% |
2019 | $8.42 B | 62.13% |
2018 | $5.19 B | -32.74% |
2017 | $7.72 B | -1.99% |
2016 | $7.88 B | 18.65% |
2015 | $6.64 B | 180.5% |
2014 | $2.36 B | -55.57% |
2013 | $5.33 B | -6.86% |
2012 | $5.72 B | 56.05% |
2011 | $3.66 B |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Pfizer PFE | $3.26 B | -47.73% | ๐บ๐ธ USA |
Eli Lilly LLY | $6.55 B | 4.87% | ๐บ๐ธ USA |
Amgen AMGN | $7.85 B | 25.68% | ๐บ๐ธ USA |
Biogen BIIB | $1.29 B | -79.25% | ๐บ๐ธ USA |
Gilead Sciences GILD | $6.85 B | 9.74% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $8.44 B | 35.04% | ๐บ๐ธ USA |
AstraZeneca AZN | $8.49 B | 35.92% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $7.53 B | 20.56% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | $0.33 B | -94.61% | ๐บ๐ธ USA |